Synapse - Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma Correspondence

Authors:	Sebastian, T.; Rajeeve, S.; Farzana, T.; Firestone, R.; Jurgens, E.; Miller, K.; Costa, B.; Lesokhin, A.; Tan, C.; Shah, G.; Korde, N.; Landau, H.; Scordo, M.; Hassoun, H.; Maclachlan, K.; Shah, U.; Hultcrantz, M.; Derkach, A.; Nemirovsky, D.; Giralt, S.; Usmani, S. Z.; Mailankody, S.; Hashmi, H.
Title:	Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
Keywords:	adult; clinical article; controlled study; aged; major clinical study; overall survival; neutropenia; cancer recurrence; letter; progression free survival; infection; multiple myeloma; thrombocytopenia; retrospective study; immunoglobulin deficiency; cytopenia; disease exacerbation; clinical outcome; overall response rate; refractory cancer; disease burden; human; male; female; b cell maturation antigen; daratumumab; chimeric antigen receptor t-cell immunotherapy; ciltacabtagene autoleucel; idecabtagene vicleucel; special situation for pharmacovigilance
Journal Title:	Blood Cancer Journal
Volume:	15
ISSN:	2044-5385
Publisher:	Nature Publishing Group
Date Published:	2025-08-14
Start Page:	137
Language:	English
DOI:	10.1038/s41408-025-01343-4
PUBMED:	40813765
PROVIDER:	scopus
PMCID:	PMC12354680
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-105013189315&doi=10.1038%2Fs41408-025-01343-4&partnerID=40&md5=823e69e4a6f2a26fec25fa08665cabd1
Notes:	Source: Scopus